Chroma’s strategy is to build a strong pipeline of first-in-class or best-in-class small molecule approaches against all key validated chromatin-related targets. Chroma plans operate a balanced portfolio by developing certain of its innovative programmes at least to human proof of concept whilst pursuing partnerships for several strategically selected programmes.